Option chain shows key data for Actuate Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Actuate Therapeutics.

Actuate Therapeutics (NASDAQ:ACTU) Stock, Option Chain

Actuate Therapeutics

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Stock Movers

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AVGO

BURU

CADL

CHCI

EVGO

GXAI

LAES

LICN

LOOP

NFBK

PLRX

PRLH

RPTX

TRUG

Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Earnings

Actuate Reports Third Quarter 2010 Financial Results: EPS of $0.23

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics Inc

Press Releases

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Analyst Ratings

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Health Care

Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Anixa Biosciences

Atossa Therapeutics

Biomea Fusion

BeyondSpring

C4 Therapeutics

Coya Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

HilleVax

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Immuneering Corporation - Class A Common Stock

Immuneering

IO Biotech

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Korro Bio

Nkarta

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tenaya Therapeutics

Vor Biopharma

Vaxart

HC Wainwright & Co.

Actuate Sftwr

Comments

Actuate Therapeutics

Actuate Therapeutics (ACTU) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell